Structure-based design and synthesis of a novel long-chain 4′′-alkyl ether derivative of EGCG as potent EGFR inhibitor: in vitro and in silico studies
Sign Up to like & getrecommendations! Published in 2022 at "RSC Advances"
DOI: 10.1039/d2ra01919a
Abstract: Herein, we report the discovery of a novel long-chain ether derivative of (−)-epigallocatechin-3-gallate (EGCG), a major green tea polyphenol as a potent EGFR inhibitor. A series of 4′′-alkyl EGCG derivatives have been synthesized via regio-selectively… read more here.
Keywords: potent egfr; c14 egcg; egcg; egfr inhibitor ... See more keywords
Skin pathologic change evaluation of the patients who had EGFR inhibitor-related skin adverse events
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz434.010
Abstract: Abstract Background Epidermal growth factor receptor (EGFR) inhibitors are a standard treatment for various malignant tumors, especially in colon cancer and lung cancer. The most common adverse reaction of EGFR inhibitors is skin toxicity, including… read more here.
Keywords: egfr; egfr inhibitor; treatment; group ... See more keywords
EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines.
Sign Up to like & getrecommendations! Published in 2023 at "Anti-cancer drugs"
DOI: 10.1097/cad.0000000000001494
Abstract: Epidermal growth factor receptor (EGFR) is one of therapeutic targets in oncology for solid tumors originating from epithelial tissue, such as non-small-cell lung carcinoma (NSCLC) and breast cancer. EGFR inhibitors used in cancer treatment may… read more here.
Keywords: egfr inhibitor; inhibitor induced; induced folliculitis; folliculitis decalvans ... See more keywords
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers
Sign Up to like & getrecommendations! Published in 2017 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.aao4307
Abstract: Chronic stress hormones promote EGFR inhibitor resistance in EGFR mutant non–small cell lung cancer. Destressing cancer with β-blockers Common wisdom holds that stress is not good for cancer patients, but it can be difficult to… read more here.
Keywords: stress hormones; egfr inhibitor; resistance; cancer ... See more keywords
Abstract 78: Inhibiting anaplastic lymphoma kinase (ALK) overcomes epidermal growth factor receptor (EGFR) inhibitor resistance in head and neck squamous cell carcinoma (HNSCC) patient-derived models
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.aacrahns17-78
Abstract: HNSCC is the sixth most common cancer worldwide. EGFR is overexpressed in up to 90% of HNSCC and associated with poor outcome. An EGFR monoclonal antibody, cetuximab, was the only approved molecular targeted therapy for… read more here.
Keywords: egfr inhibitor; alk; hnscc; resistance ... See more keywords
Dacomitinib Beats Gefitinib for EGFR+ NSCLC.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2017-089
Abstract: The irreversible EGFR inhibitor dacomitinib reduced the chance of lung cancer progression compared with an older, first-generation EGFR inhibitor, gefitinib, in a phase III trial. As reported at the 2017 American Society of Clinical Oncology… read more here.
Keywords: egfr; gefitinib egfr; egfr inhibitor; dacomitinib ... See more keywords
An in Vitro Assay of hERG K+ Channel Potency for a New EGFR Inhibitor FHND004
Sign Up to like & getrecommendations! Published in 2018 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2018.00577
Abstract: FHND004 is a newly synthesized epidermal growth factor receptor (EGFR) inhibitor for the treatment of non-small cell lung cancer (NSCLC). The aim of the present study was to investigate the impacts of FHND004 on human… read more here.
Keywords: egfr inhibitor; potency; herg; fhnd004 ... See more keywords
Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study
Sign Up to like & getrecommendations! Published in 2023 at "Molecules"
DOI: 10.3390/molecules28073014
Abstract: Targeting L858R/T790M and L858R/T790M/C797S mutant EGFR is a critical challenge in developing EGFR tyrosine kinase inhibitors to overcome drug resistance in non-small cell lung cancer (NSCLC). The discovery of next-generation EGFR tyrosine kinase inhibitors (TKIs)… read more here.
Keywords: type mutant; novel egfr; type; egfr inhibitor ... See more keywords